(VIANEWS) – Albany International Corporation (AIN), Eli Lilly and Company (LLY), PulteGroup (PHM) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Albany International Corporation (AIN)
22.9% sales growth and 12.17% return on equity
Albany International Corp. engages in the textile and materials processing businesses. The company operates in two segments, Machine Clothing (MC) and Albany Engineered Composites (AEC). The MC segment designs, manufactures, and markets paper machine clothing for use in manufacturing papers, paperboards, tissues, and towels. This segment offers forming, pressing, and drying fabrics, as well as process belts. It also provides customized and consumable fabrics that are used in the manufacturing process in the pulp, corrugator, nonwovens, fiber cement, building products, tannery, and textile industries. This segment sells its products directly to end-user customers. The AEC segment designs, develops, and manufactures composite structures primarily to customers in the commercial and defense aerospace industries. The company operates in the United States, Switzerland, France, Brazil, China, Mexico, and internationally. Albany International Corp. was founded in 1895 and is headquartered in Rochester, New Hampshire.
Earnings Per Share
As for profitability, Albany International Corporation has a trailing twelve months EPS of $3.55.
PE Ratio
Albany International Corporation has a trailing twelve months price to earnings ratio of 24.85. Meaning, the purchaser of the share is investing $24.85 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.17%.
2. Eli Lilly and Company (LLY)
17.6% sales growth and 50.75% return on equity
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Earnings Per Share
As for profitability, Eli Lilly and Company has a trailing twelve months EPS of $5.77.
PE Ratio
Eli Lilly and Company has a trailing twelve months price to earnings ratio of 130.27. Meaning, the purchaser of the share is investing $130.27 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 50.75%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Feb 14, 2024, the estimated forward annual dividend rate is 5.2 and the estimated forward annual dividend yield is 0.71%.
Volume
Today’s last reported volume for Eli Lilly and Company is 1949700 which is 36.73% below its average volume of 3081640.
Sales Growth
Eli Lilly and Company’s sales growth is 19.6% for the present quarter and 17.6% for the next.
Moving Average
Eli Lilly and Company’s worth is under its 50-day moving average of $761.53 and way higher than its 200-day moving average of $628.95.
3. PulteGroup (PHM)
9.4% sales growth and 27.3% return on equity
PulteGroup, Inc., through its subsidiaries, primarily engages in the homebuilding business in the United States. It acquires and develops land primarily for residential purposes; and constructs housing on such land. The company also offers various home designs, including single-family detached, townhomes, condominiums, and duplexes under the Centex, Pulte Homes, Del Webb, DiVosta Homes, American West, and John Wieland Homes and Neighborhoods brand names. As of December 31, 2022, it controlled 211,112 lots, of which 108,848 were owned and 102,264 were under land option agreements. In addition, the company arranges financing through the origination of mortgage loans primarily for homebuyers; sells the servicing rights for the originated loans; and provides title insurance policies, and examination and closing services to homebuyers. The company was founded in 1950 and is headquartered in Atlanta, Georgia.
Earnings Per Share
As for profitability, PulteGroup has a trailing twelve months EPS of $11.72.
PE Ratio
PulteGroup has a trailing twelve months price to earnings ratio of 9.58. Meaning, the purchaser of the share is investing $9.58 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.3%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10.4%, now sitting on 16.44B for the twelve trailing months.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Mar 14, 2024, the estimated forward annual dividend rate is 0.8 and the estimated forward annual dividend yield is 0.71%.
Moving Average
PulteGroup’s value is higher than its 50-day moving average of $110.46 and way above its 200-day moving average of $92.55.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 3.1% and positive 9.7% for the next.
4. Banco Santander Brasil (BSBR)
6.5% sales growth and 8.33% return on equity
Banco Santander (Brasil) S.A., together with its subsidiaries, provides various banking products and services to individuals, small and medium enterprises, and corporate customers in Brazil and internationally. The company operates through Commercial Banking and Global Wholesale Banking segments. It offers local loans, commercial financing options, development bank funds, and cash management services; export and import financing, guarantees, structuring of asset services. In addition, the company provides financing and advisory services for infrastructure projects and capital markets instruments, as well as offers equity transactions and mergers and acquisitions services. Further, it offers foreign exchange products, derivatives, and investments to institutional investors, corporate clients, and individuals. Additionally, the company provides research services, as well as offers brokerage services for corporate, institutional, and individual investors. Furthermore, it provides deposits and other bank funding instruments, and debit and credit cards. The company provides financial services and products to its customers through multichannel distribution network comprising branches, mini-branches, ATMs, call centers, Internet banking, and mobile banking. Banco Santander (Brasil) S.A. was incorporated in 1985 and is headquartered in São Paulo, Brazil. The company operates as a subsidiary of Banco Santander, S.A.
Earnings Per Share
As for profitability, Banco Santander Brasil has a trailing twelve months EPS of $241.25.
PE Ratio
Banco Santander Brasil has a trailing twelve months price to earnings ratio of 0.02. Meaning, the purchaser of the share is investing $0.02 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.33%.
Sales Growth
Banco Santander Brasil’s sales growth is negative 4.4% for the ongoing quarter and 6.5% for the next.
Moving Average
Banco Santander Brasil’s worth is under its 50-day moving average of $5.57 and below its 200-day moving average of $5.74.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 166.7% and 125%, respectively.
